Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 933-938

  De Vos, Lisanne C ^a   Mulder, Douwe J ^a   Smit, Andries J ^a   Dullaart, Robin P F ^a   Kleefstra, Nanne ^a   Lijfering, Willem M ^b   Kamphuisen, Pieter W ^a   Zeebregts, Clark J ^a   Lefrandt, Joop D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

advanced glycation end products; atherosclerosis; cardiovascular diseases; peripheral artery disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C;

ABDOMINAL AORTA ANEURYSM; AGE; AGED; ANKLE BRACHIAL INDEX; ARTICLE; AUTOFLUORESCENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OUTPATIENT DEPARTMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; SKIN AUTOFLUORESCENCE; SMOKING;

ADVANCED GLYCATION END PRODUCTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; PERIPHERAL ARTERY DISEASE;

AGED; BIOLOGICAL MARKERS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KAPLAN-MEIER ESTIMATE; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SKIN; STROKE; TIME FACTORS;

EID: 84897059249     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302731     Document Type: Article

References (23)

1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006;113:463-654
3. Jones WS, Patel MR, Dai D, Vemulapalli S, Subherwal S, Stafford J, Peterson ED. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J. 2013;165:805-815.
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glyca-tion end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
5. Smit AJ, Gerrits EG. Skin autofuorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:527-533.
6. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 1996;39:946-951.
7. Kralev S, Zimmerer E, Brueckmann M, Lang S, Kälsch T, Rippert A, Lin J, Borggrefe M, Hammes HP, Süselbeck T. Elevation of the glycoxida-tion product N(epsilon)-(carboxymethyl)lysine in patients presenting with acute myocardial infarction. Clin Chem Lab Med. 2009;47:446-451.
8. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofuorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J. 2009;17:162-168.
9. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.
10. de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, Kamphuisen PW, Zeebregts CJ, Lefrandt JD. Skin autofuores-cence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol. 2013;33:131-138.
11. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofuorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006;29:2654-2659.
12. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997;51:1170-1181.
13. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ. Skin autofuorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52:789-797.
14. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin autofuo-rescence, a measure of cumulative metabolic stress and advanced glyca-tion end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-3693.
15. Ohnuki Y, Nagano R, Takizawa S, Takagi S, Miyata T. Advanced gly-cation end products in patients with cerebral infarction. Intern Med. 2009;48:587-591.
16. Ikeda T, Maruyama K, Ito N, Utagawa A, Nagane M, Shiokawa Y. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J Stroke Cerebrovasc Dis. 2012;21:386-390.
17. Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, Lutgers HL, Smit AJ, Zeebregts CJ. Skin autofuorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging. 2012;28:431-438.
18. Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, Mukamal KJ. Oxidation-specifc biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013;61:2169-2179.
19. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478-2487.
20. Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-defcient mouse model of diabetes via effects on advanced glycation, oxidative stress and infammation. Diabetologia. 2008;51:1731-1740.
21. Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, Rakhorst G, Graaff R. Skin color independent assessment of aging using skin auto-fuorescence. Opt Express. 2010;18:14416-14429.
22. Hofmann B, Adam AC, Jacobs K, Riemer M, Erbs C, Bushnaq H, Simm A, Silber RE, Santos AN. Advanced glycation end product associated skin autofuorescence: a mirror of vascular function? Exp Gerontol. 2013;48:38-44.
23. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RP. Carotid artery intima media thickness associates with skin autofuoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest. 2010;40:812-817.